A new mycobacteriophage-based technique (PhageTek MB)Tuberculosis continues to be a global health problem, with more than 8 million new cases and 2 million deaths each year (24). The spread of human immunodeficiency virus (HIV) infection and the breakdown in health services have contributed to a dramatic rise in the incidence of tuberculosis. The great majority of the new tuberculosis cases (95%) and tuberculosis deaths (98%) are in developing regions such as Southeast Asia, sub-Saharan Africa, Latin America, and Eastern Europe (15,20). One of the principles of tuberculosis control is rapid and accurate diagnosis of infected patients in order to allow prompt initiation of antibiotic therapy and to prevent transmission. Although the conventional procedures are irreplaceable diagnostic tools, detection of acid-fast bacilli by microscopy shows poor sensitivity, and solid culture methods can take as long as 8 weeks (liquid culture methods are faster but unaffordable for laboratories in low-income areas). In addition, coinfection with HIV has changed the clinical presentation of tuberculosis and reduced the sensitivity of classical microbiology methods (5, 9, 17). Therefore, in developing countries, it is especially important to have an inexpensive and rapid test for tuberculosis identification so that infected individuals can be isolated and treated immediately (10).Mycobacteriophages constitute a potentially useful approach for detecting viable Mycobacterium tuberculosis bacilli as well as for susceptibility studies (22). Several mycobacteriophages have been reported to be highly specific for all M. tuberculosis complex species (11,13,25). These mycobacteriophages have been important in the development of phagebased technology, as shown in some studies (7,14,28). Their relatively rapid replication (which compensates for the otherwise slow growth of their hosts), the simplicity of the methodology, and the relatively inexpensive equipment required make the use of mycobacteriophages a suitable tool for the rapid diagnosis of tuberculosis.The PhageTek MB assay (Organon Teknika Corporation, Durham, N.C.; manufactured by Biotec Laboratories Ltd., Ipswich, United Kingdom, as a variant of its FASTPlaqueTB test) is a phenotypic assay that uses M. tuberculosis complex-specific mycobacteriophages to report the presence of live M. tuberculosis complex organisms within a sample. The target bacteria in a decontaminated respiratory specimen are rapidly infected by the target-specific bacteriophage. A selective virucide is added which, without affecting the cells, destroys all exogenous phages that have not infected the M. tuberculosis complex bacilli. The phages protected within the M. tuberculosis complex organisms replicate and form clear areas (plaques) in a lawn of rapidly growing host helper cells. Although the number of plaques generated from a given sample is related to the number of viable M. tuberculosis complex cells containing mycobacteriophage, this test is qualitative. Results from specimens can be read by eye after ...